Radiation Sensitivity, DNA Repair, and Second Cancers.
N/A
N/A
Both
Cancer
Trial Information
Radiation Sensitivity, DNA Repair, and Second Cancers.
OBJECTIVES:
Primary
- Determine whether genetic susceptibility (e.g., inherited differences in radiation
sensitivity to normal tissue or genes of xenobiotic metabolism, nucleotide provision,
or DNA repair) to the carcinogenic effects of radiotherapy, tobacco, and UV light
modifies the risk of second malignant neoplasms (SMN) in patients with cancer treated
with hematopoietic stem cell transplantation (HSCT).
Secondary
- Measure inherent sensitivity to radiotherapy via G_2 chromosome radiation sensitivity
assay using B-cell lymphoblastoid cell lines derived from pre-HSCT cryopreserved
peripheral blood mononuclear cells of patients with and without SMN.
- Measure the frequency of allelic variants of genes involved in xenobiotics metabolism,
DNA repair, and provision of nucleotide pool and compare the frequencies among patients
with and without SMN, determine the transmission of specific alleles of these genes
from parents to patients, and correlate allelic variants of DNA repair and nucleotide
provision in genes with in vitro radiation sensitivity.
- Evaluate the role of potentially carcinogenic environmental exposures (tobacco and sun
light) pre- or post-HSCT in the risk of SMN and examine the association of these
exposures with SMN and the interaction of these exposures with allelic variants of
genes involved in xenobiotic metabolism, nucleotide provision, and DNA repair.
OUTLINE: Patients complete self-reported questionnaires and medical records are reviewed to
collect information on UV light and tobacco exposure pre- and post-transplantation.
Information is analyzed for association with second malignancy neoplasms.
Blood samples are collected from patients pre-hematopoietic stem cell transplantation and
from their parents (when available) or other first-degree relatives for genetic biomarkers
of susceptibility to second malignancies, DNA repair and provision nucleotide, genetic
susceptibility to toxicity from combined cancer therapies, and environmental carcinogens.
PROJECTED ACCRUAL: A total of 1,000 patients (800 patients without second malignant
neoplasms [SMN] and 200 patients with SMN) will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Patients who survived 100 days post-hematopoietic stem cell transplantation (HSCT)
- Underwent total-body irradiation therapy as part of the preparative regimen for
HSCT
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Genetic susceptibility to the carcinogenic effects of radiotherapy, tobacco, and UV light and risk of second malignant neoplasms (SMN)
Safety Issue:
No
Principal Investigator
Debra L. Friedman, MD, MS
Investigator Role:
Principal Investigator
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
Unspecified
Study ID:
CDR0000640299
NCT ID:
NCT00949052
Start Date:
January 2009
Completion Date:
Related Keywords:
- Cancer
- cancer survivor
- stage III adult Burkitt lymphoma
- stage III adult diffuse large cell lymphoma
- stage III adult diffuse mixed cell lymphoma
- stage III adult diffuse small cleaved cell lymphoma
- stage III adult Hodgkin lymphoma
- stage III adult immunoblastic large cell lymphoma
- stage III adult lymphoblastic lymphoma
- stage III grade 1 follicular lymphoma
- stage III grade 2 follicular lymphoma
- stage III grade 3 follicular lymphoma
- stage III mantle cell lymphoma
- stage III marginal zone lymphoma
- stage III small lymphocytic lymphoma
- stage IV adult Burkitt lymphoma
- stage IV adult diffuse large cell lymphoma
- stage IV adult diffuse mixed cell lymphoma
- stage IV adult diffuse small cleaved cell lymphoma
- stage IV adult Hodgkin lymphoma
- stage IV adult immunoblastic large cell lymphoma
- stage IV adult lymphoblastic lymphoma
- stage IV grade 1 follicular lymphoma
- stage IV grade 2 follicular lymphoma
- stage IV grade 3 follicular lymphoma
- stage IV mantle cell lymphoma
- stage IV marginal zone lymphoma
- stage IV small lymphocytic lymphoma
- recurrent adult Burkitt lymphoma
- recurrent adult diffuse large cell lymphoma
- recurrent adult diffuse mixed cell lymphoma
- recurrent adult diffuse small cleaved cell lymphoma
- recurrent adult Hodgkin lymphoma
- recurrent adult immunoblastic large cell lymphoma
- recurrent adult lymphoblastic lymphoma
- recurrent childhood large cell lymphoma
- recurrent childhood lymphoblastic lymphoma
- recurrent childhood small noncleaved cell lymphoma
- recurrent cutaneous T-cell non-Hodgkin lymphoma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- recurrent grade 3 follicular lymphoma
- recurrent mantle cell lymphoma
- recurrent marginal zone lymphoma
- recurrent small lymphocytic lymphoma
- recurrent/refractory childhood Hodgkin lymphoma
- recurrent mycosis fungoides/Sezary syndrome
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- nodal marginal zone B-cell lymphoma
- splenic marginal zone lymphoma
- noncontiguous stage II adult Burkitt lymphoma
- noncontiguous stage II adult diffuse large cell lymphoma
- noncontiguous stage II adult diffuse mixed cell lymphoma
- noncontiguous stage II adult diffuse small cleaved cell lymphoma
- noncontiguous stage II adult immunoblastic large cell lymphoma
- noncontiguous stage II adult lymphoblastic lymphoma
- noncontiguous stage II grade 1 follicular lymphoma
- noncontiguous stage II grade 2 follicular lymphoma
- noncontiguous stage II grade 3 follicular lymphoma
- noncontiguous stage II mantle cell lymphoma
- noncontiguous stage II marginal zone lymphoma
- noncontiguous stage II small lymphocytic lymphoma
- accelerated phase chronic myelogenous leukemia
- adult acute lymphoblastic leukemia in remission
- adult acute myeloid leukemia in remission
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- atypical chronic myeloid leukemia, BCR-ABL negative
- blastic phase chronic myelogenous leukemia
- childhood acute lymphoblastic leukemia in remission
- childhood acute myeloid leukemia in remission
- childhood chronic myelogenous leukemia
- chronic myelomonocytic leukemia
- chronic phase chronic myelogenous leukemia
- juvenile myelomonocytic leukemia
- recurrent adult acute lymphoblastic leukemia
- recurrent adult acute myeloid leukemia
- recurrent childhood acute lymphoblastic leukemia
- recurrent childhood acute myeloid leukemia
- refractory chronic lymphocytic leukemia
- refractory hairy cell leukemia
- relapsing chronic myelogenous leukemia
- secondary acute myeloid leukemia
- stage III chronic lymphocytic leukemia
- stage IV chronic lymphocytic leukemia
- childhood myelodysplastic syndromes
- chronic eosinophilic leukemia
- primary myelofibrosis
- chronic neutrophilic leukemia
- de novo myelodysplastic syndromes
- disseminated neuroblastoma
- myelodysplastic/myeloproliferative neoplasm, unclassifiable
- poor prognosis metastatic gestational trophoblastic tumor
- previously treated childhood rhabdomyosarcoma
- previously treated myelodysplastic syndromes
- recurrent Wilms tumor and other childhood kidney tumors
- recurrent childhood rhabdomyosarcoma
- recurrent neuroblastoma
- recurrent ovarian epithelial cancer
- recurrent ovarian germ cell tumor
- recurrent malignant testicular germ cell tumor
- secondary myelodysplastic syndromes
- stage I multiple myeloma
- stage II multiple myeloma
- stage III multiple myeloma
- stage II ovarian epithelial cancer
- stage III ovarian epithelial cancer
- stage IV ovarian epithelial cancer
- stage III malignant testicular germ cell tumor
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- refractory multiple myeloma
- Lymphoma, Non-Hodgkin
- Lymphoma, Large-Cell, Immunoblastic
- Neoplasms, Second Primary
Name | Location |
|---|---|
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
| Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |
